29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): final report
1 July 2022. Related: Conference reports.
CROI 29 (Retrovirus) 2022
CROI 2022: NAMSAL study comparing DTG to EFV400 in Cameroon: week 192 results
1 July 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): further reports
1 June 2022. Related: Conference reports.
CROI 2022: Updates from the VESTED study
1 June 2022. Related: Conference reports, Treatment strategies.
CROI 2022: Switching to dolutegravir for adults on stable PI-based second-line ART
1 June 2022. Related: Conference reports, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): third reports
2 May 2022. Related: Conference reports.
CROI 2022: Dolutegravir plus recycled tenofovir rather than switch to AZT: public health approach to second-line ART
2 May 2022. Related: Conference reports, Antiretrovirals, Treatment strategies.
29th Conference on Retroviruses and Opportunistic Infections (CROI 2022): second reports
1 April 2022. Related: Conference reports.
CROI 2022: Webcasts now online and open access
1 April 2022. Related: Conference reports.
CROI 2022: Islatravir studies for HIV treatment and PrEP
1 April 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: UK study reports diabetes mellitus in 9% of HIV positive Africans in the UK on stable ART
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Life expectancy reduced by eight years following hospitalisation for a mental health condition in South Africa
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: Long COVID persists for over a year: evidence for divergent immune responses
1 April 2022. Related: Conference reports, Coinfections and complications, COVID-19: long COVID, COVID-19.
CROI 2022: Risk factors for NAFLD and proteinuria in HIV positive people on ART in the REPRIEVE study
1 April 2022. Related: Conference reports, Coinfections and complications.
CROI 2022: UK study shows PEP is started earlier using home starter packs
1 April 2022. Related: Conference reports, HIV prevention and transmission.
29th Conference on Retroviruses on Opportunistic Infections (CROI 2022): First reports
1 March 2022. Related: Conference reports.
CROI 2022: Biktarvy (B/F/TAF): 5-year follow-up in two phase 3 studies
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Injectable CAB/RPV-LA results after three years follow-up
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir: 54 week results in treatment-naive participants of CALIBRATE study
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Lenacapavir in treatment-experienced participants, and as PrEP in macaques
1 March 2022. Related: Conference reports, Antiretrovirals.
CROI 2022: Fourth potential stem cell HIV cure – in a US woman using donor cord cells
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Strategies to suppress viral load off-ART with 3BNC117, 10-1074 and other bNAbs
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Dual bNAb treatment maintains undetectable viral load off-ART in 44% of children in the Tatelo Study
1 March 2022. Related: Conference reports, Paediatric care, Cure-related research.
CROI 2022: AAV8-VRC07 vaccine generates new bNAb production in HIV positive people for up to three years
1 March 2022. Related: Conference reports, Cure-related research.
CROI 2022: Higher maternal mortality and adverse birth outcomes among women with COVID-19 in Botswana
1 March 2022. Related: Conference reports, Women's health, Pregnancy.
CROI 2022: ANCHOR study reduces anal cancer by 57% and supports screening for people living with HIV
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Other studies on anal cancer
1 March 2022. Related: Conference reports, Cancer and HIV.
CROI 2022: Telomere shortening associated with TAF but not TDF in CHARTER study
1 March 2022. Related: Conference reports, Basic science and immunology, Ageing and life expectancy.
CROI 2022: Injectable PrEP: impressive results, new viral load monitoring – but price questions access
1 March 2022. Related: Conference reports, HIV prevention and transmission.
CROI 2022: LEAP Workshop online: research into long-acting drugs
1 March 2022. Related: Conference reports, On the web.
CROI 2022 to only be virtual: programme online
7 February 2022. Related: Conference reports.